Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 10/20 | 0.46 |
| ▸ | CCR2 | P41597 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29830171 | 1.00 | SGK1 (0.46) | SGK1CCR2CYP1A2SLC40A1SLC6A4 | |
| SCHEMBL23610285 | 0.88 | SGK1 (0.43) | SGK1CCR2CYP1A2SLC40A1 | |
| SCHEMBL29829649 | 0.88 | SGK1 (0.43) | SGK1CCR2CYP1A2SLC40A1 | |
| SCHEMBL21596696 | 0.86 | CCR2 (0.43) | SGK1CCR2SLC40A1 | |
| SCHEMBL29365104 | 0.86 | CCR2 (0.43) | SGK1CCR2SLC40A1 | |
| SCHEMBL21596681 | 0.86 | SGK1 (0.40) | SGK1CCR2CYP1A2 | |
| SCHEMBL29829557 | 0.86 | SGK1 (0.40) | SGK1CCR2CYP1A2 | |
| SCHEMBL21596663 | 0.84 | CCR2 (0.44) | SGK1CCR2SLC40A1 | |
| SCHEMBL29829935 | 0.84 | CCR2 (0.44) | SGK1CCR2SLC40A1 | |
| SCHEMBL21596672 | 0.82 | SGK1 (0.42) | SGK1CCR2SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112469710-B | Pyridyl and pyrazinyl- (aza) indole sulfonamides | 优时比制药有限公司 | 2024-05-14 | — | — | CN | claimed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | claimed |
| EP-3810591-B1 | PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2022-08-10 | — | — | EP | claimed |
| US-20210206749-A1 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | UCB PHARMA GMBH (DE) | 2021-07-08 | — | — | US | claimed |
| CN-112469710-A | Pyridyl and pyrazinyl- (aza) indole sulfonamides | 优时比制药有限公司 | 2021-03-09 | — | — | CN | claimed |
| CN-112469710-B | Pyridyl and pyrazinyl- (aza) indole sulfonamides | 优时比制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| EP-4074703-B1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| EP-4074703-B1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| EP-4074703-A1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB Pharma GmbH (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-4074703-A1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB Pharma GmbH (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-3810591-B1 | PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2022-08-10 | — | — | EP | disclosed |
| US-20210206749-A1 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | UCB PHARMA GMBH (DE) | 2021-07-08 | — | — | US | disclosed |
| US-20210206749-A1 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | UCB PHARMA GMBH (DE) | 2021-07-08 | — | — | US | disclosed |
| CN-112469710-A | Pyridyl and pyrazinyl- (aza) indole sulfonamides | 优时比制药有限公司 | 2021-03-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206749-A1 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | GPR17, GPR18, GPR119 | SGK1 1683/4885CCR2 916/4885CYP1A2 1013/4885 |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | GPR17, GPR18, GPR119 | SGK1 1683/4885CCR2 916/4885CYP1A2 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.